F ibrosis of the heart is driven by the reprogramming of resident fibroblasts into contractile myofibroblasts that express high levels of extracellular matrix. Cardiac fibrosis may be beneficial, replenishing regions of myocyte loss with a structural scar after infarction, or maladaptive, involving excess extracellular matrix deposition in response to long-standing stress. Uncontrolled cardiac fibrosis can have dire consequences. For example, fibrosis increases the passive stiffness of the myocardium, contributing to diastolic dysfunction, and disrupts electric conduction in the heart, causing arrhythmias and sudden cardiac death. Clinical trials aimed at treating heart failure with preserved ejection fraction, in part by blocking cardiac fibrosis, have mainly centered on inhibiting components of the renin-angiotensinaldosterone system and have largely been unsuccessful. 1 As such, cardiac fibrosis is a major unmet medical need, and the discovery of new mechanisms that control fibrosis in the heart is required for development of innovative therapies for this prominent and devastating process.
Transforming growth factor (TGF)-β is a cytokine that controls fibrosis across organ systems. Binding of TGF-β to its cell surface receptor triggers phosphorylation and nuclear translocation of SMAD transcription factors, which bind regulatory elements in a variety of profibrotic genes. An article published by Molkentin et al in this issue of Circulation 2 defines a crucial role for noncanonical, SMADindependent TGF-β signaling in the control of cardiac fibrosis. In a tour-de-force of elegant genetic gain-and loss-of-function studies, the authors demonstrate that the mitogen-activated protein kinase p38α is a nodal effector of profibrotic TGF-β signaling in the heart. These findings were reported in this seminal article:
1. p38α (Mapk14 gene) deletion in cultured fibroblasts blocked differentiation of the cells into α-smooth muscle actin-positive myofibroblasts in response to TGF-β, angiotensin II, or cyclic stretching. 2. The block to myofibroblast differentiation in cultured fibroblasts lacking p38α could be overcome by ectopic overexpression of the canonical transient receptor potential 6 channel, a constitutively active form of the calcineurin phosphatase, or the serum response factor transcription factor, suggesting that p38α lies upstream of these proteins ( Figure) , which were previously shown by the Molkentin group to regulate myofibroblast differentiation. 3 3. In vivo, conditional deletion of p38α in unstimulated, tissue-resident fibroblasts using inducible Tcf21-Cre 4,5 led to cardiac rupture in 100% of the mice in response to chronic coronary artery ligation and also increased mortality after cardiac ischemia-reperfusion (I/R). p38α-null mice that survived the I/R procedure exhibited significantly reduced cardiac fibrosis and improved diastolic function 28 days after surgery compared with controls. The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association. 4 . Mice with deletion of p38α in activated fibroblasts via inducible periostin-Cre 5 had reduced cardiac fibrosis in response to I/R or chronic infusion of angiotensin II and phenylephrine. These animals succumbed to cardiac rupture less frequently than mice in which p38α was deleted using Tcf21-Cre, suggesting more efficient formation of the reparative scar. 5. In a model of dermal wound healing, deletion of p38α using periostin-Cre also blocked fibrosis, underscoring that this kinase regulates both physiological and pathological fibrosis. 6. Ectopic expression of the p38α activator, MAPK kinase 6, in fibroblasts using Tcf21-Cre led to profound cardiac fibrosis and diastolic dysfunction. In mice where MKK6 expression was driven by periostin-Cre, increased cardiac fibrosis was observed after I/R or chronic angiotensin II/phenylephrine treatment compared with control littermates.
Other intriguing findings less prominently featured in the article include:
1. Tcf-21-Cre/MKK6 transgenic mice also develop prominent renal and pulmonary fibrosis. Thus, this model could be extremely useful for testing efficacy of novel antifibrotic strategies, particularly for lung fibrosis, where the most common preclinical model (rodent intratracheal instillation of bleomycin) has many weaknesses. 6, 7 2. Fibroblast deletion of p38α using periostin-Cre led to reduced cardiac hypertrophy in response to angiotensin II/phenylephrine infusion, suggesting a role for this kinase in fibroblast-to-myocyte crosstalk in the control of hypertrophic growth. 3. Fibroblasts lacking p38α exhibited higher proliferation rates compared with wild-type controls, suggesting that the inability of p38α-deleted cells to differentiate into myofibroblasts is possibly related to a failure to effectively exit the cell cycle. 4. Deletion of p38α with periostin-Cre reduced cardiac fibrosis in mice subjected to I/R but did not lead to improved diastolic function, suggesting that mechanisms in addition to fibrosis control diastolic relaxation. The in vivo data conclusively demonstrate a crucial role for p38α in the control of both physiological and pathological fibrosis. The findings from mechanistic studies with cultured fibroblasts, which suggest that canonical transient receptor potential 6, calcineurin, and serum response factor lie downstream of p38α in the regulation of myofibroblast differentiation, are compelling and should be further validated using loss-of-function approaches. For example, the impact of knocking down the expression of each of these factors, alone or in combination, on myofibroblast differentiation should be assessed in fibroblasts expressing constitutively active MKK6. Furthermore, future quantitative phosphoproteomics studies should provide valuable mechanistic insight into which p38α substrates govern profibrotic signaling in fibroblasts.
Above anything else, the data presented in this article suggest great potential for small molecule inhibitors of p38α for the treatment of pathological fibrosis. In this regard, it should be noted that there are only 2 US Food and Drug Administration-approved antifibrotic therapies, both of which are currently restricted to the treatment of pulmonary fibrosis. 8 It has been >2 decades since the first discovery that p38 kinase inhibition exhibited anti-inflammatory therapeutic potential. 9 Although initial drug development efforts focused on rheumatoid arthritis, considerable expansion in therapeutic focus has occurred over time. A wide variety of disease areas have been interrogated in phase 2 clinical trials with p38 inhibitors, including asthma, chronic obstructive pulmonary disorder, pain, cancer, Alzheimer's disease, and cardiovascular disease. Within fibroblasts, p38α promotes serum response factor (SRF) transcriptional activity and enhances calcineurin-nuclear factor of activated T cells (NFAT) signaling via canonical transient receptor potential 6 (TRPC6). Together, SRF and NFAT activate genes that promote myofibroblast differentiation and fibrosis. SRF and NFAT also stimulate TRPC6 expression, creating a profibrotic positive feedback loop, and appear to promote expression of factors that function in a paracrine manner to stimulate cardiac hypertrophy. Small molecule inhibitors of p38α or upstream kinases, such as apoptosis signal-regulating kinase 1 (ASK1), have the potential to block cardiac fibrosis. MKK6 indicates MAPK kinase 6; and TGF, transforming growth factor.
Currently, 45 clinical trials that include a p38 inhibitor are cataloged at clinicaltrials.gov, which represents 15 distinct chemical entities being pursued by 11 different drug development companies. More than 70% of these clinical trials are classified as phase 2 or phase 1/2, and only 1 phase 3 trial is listed (LATITUDE-TIMI 60 [Losmapimod to Inhibit p38 MAP Kinase as a Therapeutic Target and Modify Outcomes After an Acute Coronary Syndrome]). The failure of most p38 inhibitors to transition into large phase 3 studies highlights the challenges of targeting this kinase to treat human diseases, namely, a lack of efficacy as a monotherapy and in many cases the inability to separate a therapeutic effect from associated toxicities (eg, liver, central nervous system, and skin). 10 LATITUDE-TIMI 60 is the largest clinical trial of a p38 inhibitor to date. 11 Unfortunately, like many of its predecessors in the phase 2 graveyard, losmapimod exhibited a lack of efficacy, failing to reduce composite cardiovascular death, myocardial infarction, or severe recurrent ischemia requiring coronary revascularization at 12 weeks; cardiac fibrosis was not assessed in this trial.
With the vast amount of preclinical support for p38 as a valid therapeutic target in a host of different diseases and pathological processes, such as fibrosis, we are left with many unanswered questions. Do our animal models accurately emulate the human disease state(s)? Would efficacy improve with p38 inhibitors that have different isoform selectivity profiles? Should p38 inhibition only be considered in combination with other therapeutics, or perhaps should we be looking upstream of p38? 10 With regard to the latter question, an inhibitor (selonsertib) of apoptosis signal-regulating kinase 1, which is an upstream activator of p38, was recently shown to reduce liver fibrosis in patients with nonalcoholic steatohepatitis, suggesting potential for this approach for the treatment of cardiac fibrosis.
Until recently, correlating fibrosis with cardiac disease was restricted to histological quantification of fibrotic lesions in explanted or cadaveric hearts. However, significant advances in imaging now provide a noninvasive means of measuring cardiac fibrosis in patients, with cardiac MRI as the current state of the art. 12 Based on the robust in vivo validation data provided by Molkentin et al, 2 coupled with exhaustive preclinical efficacy data with p38 catalytic inhibitors in models of heart failure, 13, 14 additional testing of a p38 inhibitor for cardiac efficacy is warranted. A small, phase 2a proof-of-concept trial would be ideal, perhaps in patients suffering from heart failure with preserved ejection fraction and using cardiac MRI for noninvasive assessment of effects of p38 inhibition on cardiac fibrosis.
